Skip to Content
Current OncologyCurrent Oncology
  • Review
  • Open Access

18 June 2026

24 Pages

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions

,
and
Bone Marrow Transplant Program, Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada
*
Author to whom correspondence should be addressed.

Simple Summary

Acute myeloid leukemia is an aggressive blood cancer with a high risk of returning even after patients achieve remission with intensive treatment. Preventing relapse remains one of the biggest challenges, especially for individuals who are not candidates for stem cell transplantation or who remain at high risk after transplant. In recent years, maintenance therapy—lower-intensity treatment given after remission—has emerged as a promising strategy to reduce relapse risk. New targeted medicines and oral treatments have shown encouraging results in selected groups of patients. This review summarizes current evidence supporting maintenance approaches and discusses how risk-adapted strategies could improve long-term outcomes and direct future research and clinical practice in acute myeloid leukemia.

Abstract

The management of acute myeloid leukemia (AML) remains characterized by high relapse rates despite advances in induction and consolidation therapy. Relapse prevention represents a major unmet need, particularly in patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) or at high risk of post-transplant recurrence. This review examines current evidence supporting maintenance strategies following intensive chemotherapy or allo-HSCT, with emphasis on measurable residual disease (MRD)-guided approaches and targeted therapies. We summarize data from randomized and phase II/III trials evaluating hypomethylating agents, FLT3 inhibitors, IDH inhibitors, and immunotherapeutic strategies in post-remission settings. Oral azacitidine (CC-486) demonstrated overall survival benefit in older patients in first complete remission who were not transplant candidates, establishing a standard of care in this population. In FLT3-mutated AML, post-transplant maintenance with sorafenib and gilteritinib reduces relapse risk, with emerging evidence supporting MRD as a predictive biomarker for benefit. Other targeted agents and immunotherapies have shown promising early-phase results, although confirmatory data are limited. Ongoing phase III studies will clarify optimal patient selection, treatment duration, and integration with transplantation, aiming to transform post-remission management from passive surveillance to precision-based relapse prevention.

1. Introduction

Despite recent advances in the treatment of acute myeloid leukemia (AML), many patients relapse after initially achieving complete remission (CR) with intensive chemotherapy (IC) [1]. Patients at high risk of relapse, either due to high-risk genomic profiles or persistent measurable residual disease (MRD), are generally recommended to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT), which remains the only potentially curative option for most [1].
However, not all patients who achieve remission with front-line IC undergo allo-HSCT due to factors such as AML risk status, eligibility criteria, lack of access to treatment, toxicities experienced during IC, comorbidities, and patient preference. Even among those who undergo allo-HSCT in first CR, the relapse rate remains approximately 30–40% within the first 2–3 years [2].
In acute lymphoblastic leukemia (ALL), the role of maintenance therapy is well understood and has been established as a critical component of therapy. In AML, the concept of maintenance therapy was described over 50 years ago, but the more widespread use of maintenance in AML is more recent [1,2,3]. Maintenance and pre-emptive therapy are two main categories of interventions which can be used following IC or post- allo-HSCT, which aim to reduce relapse risk trying to balance against potential toxicity. Pre-emptive therapy is initiated in response to early molecular or immunologic evidence of relapse such as MRD positivity or declining donor chimerism, whereas maintenance therapy may be given to a broad group at higher risk of relapse, with the purpose to prolong remission and improve survival while allowing for acceptable quality of life. There is overlap between both strategies and although there is no formal definition of maintenance therapy, this is generally given over relatively longer periods of time and is consequently less intensive and requires a more tolerable side-effect profile. With both strategies, the risk of relapse must be balanced with potential for toxicity and concerns about overtreatment. For this review, we will focus on maintenance strategies, occasionally referring to pre-emptive therapy in situations where these strategies overlap [4].
In AML, maintenance therapy is most frequently used and investigated in the following two main settings: the first includes patients who achieve remission after induction and consolidation chemotherapy but do not undergo allo-HSCT due to risk status, eligibility, preferences, lack of donor availability, or disease characteristics. The second setting is in patients following allo-HSCT, particularly those at high risk of relapse, such as those with adverse genetic profiles or with MRD positivity, with the goal of enhancing the graft-versus-leukemia effect (GVLE) and reducing post-transplant relapse [5,6,7]. The currently approved and/or guideline-recommended maintenance therapies are shown in Figure 1 and described in Table 1 and Table 2. However, there are still several questions about the use of maintenance such as the following: which AML patients may benefit most from maintenance and what are the optimal treatments as well as duration for this therapy?
Figure 1. Recommendations for maintenance therapies in acute myeloid leukemia.
Table 1. Regulatory approval status and guideline recommendations for maintenance therapies in acute myeloid leukemia.
Table 2. Approved/recommended therapies for maintenance in acute myeloid leukemia.

2. MRD Guiding Maintenance

MRD represents the presence of residual leukemic cells below the threshold of morphological detection and is a powerful prognostic biomarker in AML. MRD positivity should not be interpreted as equivalent to morphologic relapse, but rather as the persistence or re-emergence of these cells below the threshold of conventional morphologic detection identifying a population at substantially increased risk of subsequent relapse. Detectable MRD after induction or consolidation strongly predicts relapse risk, whereas MRD negativity is associated with longer overall survival (OS) and relapse-free survival (RFS), making it a potentially valuable tool for guiding post-remission therapy [8,9]. While MRD positivity frequently precedes overt disease recurrence, not all patients with detectable MRD will experience immediate clinical relapse. Due to this strong correlation, MRD is being increasingly evaluated as a tool to individualize maintenance therapy decisions. An ideal MRD biomarker should be specific to leukemic cells, stable over the disease course, relevant for monitoring, and resistant to clonal heterogeneity or evolution. Advances in MRD detection—including multiparameter flow cytometry (MFC), quantitative polymerase chain reaction (qPCR), real-time qPCR (RT-qPCR), digital droplet PCR (ddPCR), and next-generation sequencing (NGS)—now allow detection of residual leukemic cells at sensitivities ranging from 10−4 to 10−6 [8,9].
The major challenge remains to identify the most sensitive and specific method for each AML subtype to guide maintenance therapy decisions effectively. According to the recent European Leukemia Network (ELN) 2025 guidelines, MRD monitoring should be performed broadly for a patient with AML following IC and before and after allo-HSCT. These guidelines include recommendations for molecular monitoring methodology for patients with mutated NPM1, FLT3-ITD, core-binding factor leukemia and KMT2A rearranged leukemia as well generally recommending MFC for other AML subsets. These recommendations highlight that MRD persistence can be used to identify high-risk patients who may benefit from maintenance or pre-emptive therapies, although the optimal intervention in most cases is still unknown.
Accumulating clinical evidence suggests that high-risk MRD-positive patients, particularly those harboring FLT3-ITD mutations, are the most likely to benefit from maintenance strategies following chemotherapy or transplantation. In contrast, the benefit of maintenance in MRD-negative patients remains less certain, although relapse rates of approximately 30% have still been reported in this group [9]. Ongoing and recently completed trials, such as MORPHO, help to clarify the predictive role of MRD in guiding targeted maintenance approaches and will be discussed later in the targeted therapy section.
For patients without actionable molecular targets, the role of MRD-guided maintenance is less clearly defined. In this context, pre-emptive treatment strategies have gained interest. The RELAZA2 trial demonstrated that initiating hypomethylating agents at the time of MRD positivity, rather than waiting for morphologic relapse, is feasible and may delay disease progression [10]. Similarly, the QUAZAR AML-001 trial provided important insights into the relationship between MRD dynamics and clinical outcomes. Patients receiving oral azacitidine (CC-486) showed higher rates of MRD clearance compared with placebo (37% vs. 19%) [11], and conversion to MRD negativity was associated with significantly longer OS (median OS 41.3 months vs. 9.0 months in patients with persistent MRD positivity; HR 0.21, 95% CI 0.14–0.32) [3]. Moreover, CC-486 appeared to be effective in prolonging remission duration regardless of initial MRD status [3,12].
Therefore, MRD currently serves more as a tool to guide pre-emptive intervention rather than as a definitive determinant for maintenance therapy selection [13]. However, as previously mentioned, in FLT3-ITD-positive AML, detectable MRD seems to identify a high-risk subgroup in which maintenance therapy may offer significant clinical benefit.
Further prospective studies are needed to define optimal MRD thresholds, timing of intervention, and the most effective therapeutic agents in this evolving treatment paradigm.

3. Hypomethylating Agents

Hypomethylating agents (HMAs) have been investigated as maintenance in AML in several clinical trials likely due to the broad applicability of these drugs and generally tolerable side-effect profile. CC-486 is currently the only non-targeted therapy approved by both the Food and Drug Administration (FDA), European Medicines Agency (EMAs) and Health Canada (HC) for maintenance therapy in AML patients who achieve CR or CRi following induction chemotherapy and are ineligible for allo-HSCT [3]. The QUAZAR AML-001 study leading to this approval included patients with AML in CR1, age 55 or older, intermediate or adverse cytogenetics who were not candidates for allo-HSCT [3]. Patients were randomized to CC-486 given at 300 mg per day for 14/28 days cycle versus placebo. The primary endpoint for the study was OS and this was 24.7 months in the CC-486 arm vs. 14.8 months in the placebo arm (p < 0.001). In longer-term follow-up of the study, 3-year OS was 37.4% in the CC-486 arm vs. 27.9% in the placebo arm. Factors associated with longer OS included: mutated NPM1, intermediate risk cytogenetics and MRD-negativity by flow cytometry (<0.1%) at the time of enrolment [14].
In the Dutch–Belgian Hemato-Oncology Cooperative Group (HOVON97), the effect of subcutaneous azacitidine was studied following IC; notably these patients did not receive any consolidation therapy before study entry [15]. In this open-label study, patients in CR/CRi were randomized to azacitidine 50 mg/m2 for 5/28 days for 12 cycles or observation. The study’s primary endpoint was disease-free survival (DFS) and this was significantly higher in the azacitidine arm (64% vs. 42% at 12 months, p = 0.04), although OS was not significantly different.
Subcutaneous azacitidine was also studied as maintenance in the post-allo-HSCT setting in a single-center clinical trial conducted by MD Anderson Cancer Center [16]. In the study, patients were randomized 1:1 to azacitidine given at 32 mg/m2 for 5/28 days or observation and there was no significant difference in RFS or OS between treatment arms. One recent randomized, controlled trial evaluated the effect of prophylactic recombinant human G-CSF (rhG-CSF) combined with minimal-dose decitabine on relapse in patients with high-risk, MRD-negative AML after allo-HSCT. In this open-label, multicenter phase II study, 204 patients who were MRD-negative post-transplant were randomized to receive either rhG-CSF plus low-dose decitabine maintenance or no intervention. The combined regimen significantly reduced the 2-year cumulative incidence of relapse (15.0% vs. 38.3% in controls; HR 0.32) and was associated with increases in lymphocyte subsets implicated in GVLE activity without increasing chronic graft versus host disease (cGVHD) [17].
Long-term hypomethylating agent plus venetoclax (HMA/VEN) therapy is not formally considered maintenance treatment, but in patients with sustained remission and MRD negativity it may serve a maintenance-like role. A subset of patients achieves prolonged remissions and OS exceeding five years, prompting interest in defining the optimal treatment duration. Retrospective data from 29 AML patients showed that over 50% of those who electively discontinued therapy remained in remission, with a median treatment-free remission of 45.8 months. Durable outcomes were most commonly observed in patients with MRD-negative status and favorable molecular features such as NPM1 or IDH2 mutation [18]. However, evidence supporting treatment discontinuation remains limited to small, retrospective, non-randomized studies, and prospective MRD-guided discontinuation trials ongoing before this approach can be adopted as standard practice.

4. FLT3 Inhibitors

FLT3 mutations are one of the most commonly found molecular aberrations in AML. FLT3-internal tandem duplications (FLT3-ITD) are present in approximately 25% of adults, and FLT3-tyrosine kinase domain (FLT3-TKD) mutations constitute 10% of AML cases [19,20]. Both FLT3 mutations lead to constitutive activation of FLT3 receptors. These mutations are associated with clinically proliferative disease and have historically been associated with higher relapse and worse OS; according to 2022 ELN guidelines patients with FLT3-ITD are now classified as intermediate risk regardless of NPM1 mutation status or allelic ratio, unless adverse cytogenetic features are also present [21]. Nevertheless, even after allo-HSCT, risk of relapse remains relatively high and there is a need for improved therapeutic strategies in this population [20,22]. The first generation of FLT3 inhibitors are multi-targeted kinase inhibitors and include midostaurin, sorafenib, and lestaurtinib, which also demonstrated in vitro inhibition of the FLT3 receptor. Second-generation FLT3 inhibitors include quizartinib, crenolanib, and gilteritinib, which have more selective inhibitory activity, as well as higher potency, compared to first-generation compounds [22]. Gilteritinib and crenolanib are active for FLT3-ITD and TKD mutations whereas quizartinib is active only for FLT3-ITD [23].
Sorafenib is a multikinase inhibitor used in treatment of renal and hepatic carcinoma but has also been studied as maintenance therapy for AML, where it has shown a reduction in relapse and improvements in RFS and OS. In a phase I post-transplant study, 22 patients received sorafenib, with the maximum tolerated dose (MTD) determined to be 400 mg twice daily. In the phase II SORMAIN trial, 83 patients were randomized to sorafenib (n = 43) or placebo (n = 40) as post-transplant maintenance. Sorafenib was given at a target dose of 400 mg twice daily for a 2-year period, although a significant number of patients were given attenuated doses to mitigate side effects. Sorafenib significantly improved 2-year RFS compared with placebo (85% vs. 53.3%; HR 0.256, 95% CI 0.10–0.65; p = 0.002). Subset analysis suggested benefit in MRD-negative and MRD-positive patients, although this was based on small numbers of patients [24]. A randomized phase III trial from China (Xuan et al., n = 202) also supports sorafenib maintenance [25]. Patients in this study received either sorafenib 400 mg twice daily (n = 100) or placebo (n = 102) until day 180 post-transplant. With a median follow-up of 60 months, sorafenib was associated with improved OS (72.0% vs. 55.9%; HR 0.55, 95% CI 0.34–0.88; p = 0.011), improved leukemia-free survival (LFS) (70.0% vs. 49.0%; HR 0.47, 95% CI 0.30–0.73; p = 0.0007), and reduced relapse risk (15.0% vs. 36.3%; HR 0.33, 95% CI 0.18–0.60; p = 0.0003), without increasing non-relapse mortality (15.0% vs. 14.7%; HR 0.79, 95% CI 0.39–1.62; p = 0.98) or the incidence of GVHD [25]. Sorafenib appeared to have efficacy in both MRD-negative and -positive groups, although MRD positivity was associated with worse outcome overall in multivariate analysis. In both the SORMAIN and phase 3 studies, the sorafenib appeared to be tolerable for most patients but was associated with higher rates of study drug discontinuation and skin toxicity, which is a known toxicity of the drug [26,27]. In Canada, there is no Health Canada approval for sorafenib, and the drug is not reimbursed by provincial funding plans.
Gilteritinib maintenance has been supported through single-center and retrospective experiences included in meta-analyses and real-world data [28]. A post hoc analysis of the phase III ADMIRAL trial evaluating patients with FLT3-mutated relapsed/refractory AML initially reported benefit for gilteritinib maintenance after HSCT. This analysis found that patients who resumed gilteritinib after allo-HSCT had lower relapse rates and improved OS compared with those who did not, and the drug was generally well-tolerated. However, the analysis was limited by a small sample size and the lack of a second randomization at the maintenance phase [29]. The efficacy of gilteritinib as post-transplant maintenance was further evaluated in the randomized phase III MORPHO (BMT CTN 1506) trial [30]. This study enrolled 356 patients in CR1, more than half of whom had received FLT3 inhibitors with initial therapy pre-transplant. Gilteritinib was administered at 120 mg daily for up to 24 months, with RFS as the primary endpoint. For the overall cohort, gilteritinib was associated with a higher RFS, although the difference was not statistically significant (HR 0.679; 95% CI, 0.459–1.005; p = 0.0518). Importantly, 24 months after transplant, a subgroup of patients with detectable pre- or post-transplant MRD (~50% of patients), assessed using a highly sensitive PCR-NGS FLT3-ITD assay (LOD ~ 1 × 10−6), derived significant RFS benefit from gilteritinib (HR 0.515; 95% CI, 0.316–0.838; p = 0.0065). In contrast, MRD-negative patients achieved favorable outcomes without additional therapy, suggesting that MRD status can help identify patients who might safely avoid maintenance. Myelosuppression was the most common adverse event and the primary cause of early treatment discontinuation [30]. Overall, this identified MRD as a predictive biomarker for this treatment [24,25] and Clinical Practice Guidelines in Oncology (NCCN Guidelines®) [31] recommend gilteritinib as the preferred post-transplant maintenance option for AML with FLT3-ITD in CR1 without MRD negativity by ultrasensitive assay pre-transplant, and it is also recommended for FLT3-TKD mutations. Consensus document from the ELN-DAVID MRD Working Party also recommends gilteritinib maintenance for patients found to be MRD-positive (FLT3-ITD by UHS-NGS MRD) either before or around day 30 after allo-HSCT, particularly in those with a single FLT3-ITD clone and concurrent NPM1 mutation, based on subgroup analysis of this trial (recommendation A15) [32].
A phase 2 study (GOSSAMER) also evaluated gilteritinib as maintenance therapy in patients with FLT3-ITD AML in CR1 following induction or consolidation therapy without plan for allo-HSCT [33]. Patients in this study were randomized 2:1 to receive gilteritinib or placebo given at a dose of 120 mg/day for up to 2 years. Although the primary endpoint of RFS was not significantly different between gilteritinib and placebo arms (HR 0.74; 95% CI, 0.41–1.34; p = 0.16), a trend toward potential benefit was observed, with RFS rates of 68.5% versus 55.3% at 1 year and 51.8% versus 44.9% at 2 years for gilteritinib versus placebo, respectively.
In the phase 3 RATIFY trial, patients in remission after consolidation continued maintenance with midostaurin or placebo according to their assigned treatment group. OS and event-free survival (EFS) were significantly improved with midostaurin plus standard chemotherapy compared with placebo, with similar rates of severe adverse events between groups. Four-year OS was 51.4% with midostaurin versus 44.3% with placebo [34]. A post hoc sensitivity analysis censoring for allo-HSCT showed a 24.3% lower risk of death with midostaurin, although the difference in four-year OS rates was not statistically significant (63.7% vs. 55.7%; p = 0.08). A post hoc landmark analysis including all patients who started maintenance, regardless of prior midostaurin exposure, showed no significant differences in OS or DFS between midostaurin and placebo during or after the 12 maintenance cycles. Median OS was not reached for either arm (HR: 0.80; 95% CI, 0.50–1.28; p = 0.3528), and median DFS was 39.4 and 56.3 months for midostaurin and placebo, respectively (HR: 0.99; 95% CI, 0.67–1.48; p = 0.9744). In the phase II RADIUS trial [35] FLT3-ITD-mutated AML patients receiving allo-HSCT were randomized to receive midostaurin for twelve 4-week cycles or standard-of-care treatments. The trial reported that midostaurin was well-tolerated and did not increase the risk of GVHD with gastrointestinal toxicities being the most common adverse events, consistent with its pre-transplant profile. The study enrolled only 60 patients and did not meet its primary endpoint and 18-month RFS was 89% in the midostaurin arm and 76% in the standard-of-care (SOC) arm (HR 0.46 [95% CI, 0.12–1.86]; p = 0.27) [35]. These findings have not led to formal recommendations for use, and the benefit of midostaurin maintenance remains uncertain.
Quizartinib, recently approved for frontline treatment of FLT3-ITD-mutated AML, has also been evaluated as maintenance therapy. In the QuANTUM-First study, quizartinib demonstrated an OS benefit compared with placebo [36]. Approvals were based on the phase III QuANTUM-First trial, which randomized 539 patients aged 18–75 years with newly diagnosed FLT3-ITD AML to quizartinib or placebo plus intensive 7+3 induction chemotherapy and High-Dose Cytarabine (HiDAC) consolidation (±allo-HSCT), followed by up to 3 years of quizartinib maintenance. Compared with placebo, quizartinib prolonged OS (31.9 vs. 15.1 months; HR 0.78; 95% CI, 0.62–0.98; p = 0.032) and showed a trend towards improved OS when censoring for allo-HSCT (HR 0.75; 95% CI, 0.56–1.01). CR duration was also longer with quizartinib versus placebo (median 38.6 vs. 12.4 months; HR 0.62; 95% CI, 0.45–0.86). Among the 89 patients who received quizartinib or placebo as maintenance after consolidation, the HR for OS was 0.4 (95% CI, 0.19–0.84). Rates of grade ≥ 3 adverse events were similar across arms (~90%), but grade ≥ 3 neutropenia (18% vs. 9%) and discontinuation due to adverse events (AEs) (20% vs. 9%) was increased in the experimental arm [36]. These findings support a potential benefit of quizartinib maintenance in patients who did not undergo allo-HSCT. Overall the positive results of the QuANTUM-First trial led to the FDA and EMA approval of quizartinib in 2023 for use in combination with cytarabine and anthracycline induction, cytarabine consolidation and as monotherapy maintenance in newly diagnosed FLT3-ITD AML [37,38]. In contrast, in a subset analysis of patients undergoing HSCT there was not clear benefit of quizartinib maintenance in this setting with no significant difference between groups. As the QuANTUM-First results were published after the last ELN update (2022), there are no formal ELN maintenance recommendations although quizartinib maintenance is included as an option following consolidation and allo-HSCT in NCCN guidelines [31] and in the provisional funding agreement (PFA) of the Canadian Drug Agency (CDA).
Additionally, crenolanib has been studied in a phase II trial in FLT3-ITD or FLT3-TKD (D835)-positive AML, assessing progression-free survival (PFS). The study included 30 patients; all enrolled patients underwent allo-HSCT and 20 of them received crenolanib as maintenance for at least 28 days. This study provides preliminary evidence that crenolanib post-allo HSCT is feasible and safe, but the lack of randomized controlled data prevents making definitive recommendations [39]. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing and may provide more information.

5. Other Targeted Agents

IDH inhibitors have also been investigated as maintenance therapy. Ivosidenib and olutasidenib are oral inhibitors targeting mutant IDH1 and are approved by the FDA for R/R AML [40,41]. Ivosidenib is also approved in combination with azacitidine in the frontline setting for older and unfit patients with newly diagnosed AML by the FDA, Health Canada and in Europe [42,43]. Enasidenib is an oral inhibitor of mutant IDH2 approved by the FDA for R/R AML [44] and previously also by Health Canada but this was withdrawn following the results of a negative phase 3 study [44,45]. Both ivosidenib and enasidenib have been studied post-allo-HSCT. In a phase I trial, enasidenib was administered to 19 patients at 100 mg daily for 12 cycles starting 30 to 90 days post-transplant, achieving a two-year PFS of 69% and OS of 74%, with a cumulative incidence of relapse of 16% and limited GVHD events [46]. Similarly, ivosidenib at 500 mg daily was used post-allo-HSCT in 16 patients, resulting in a two-year PFS of 81%, OS of 88%, cumulative incidence of relapse of 19%, and non-relapse mortality of 0% [47]. Both drugs demonstrated promising safety profiles with limited toxicity and low risk of GVHD, supporting their consideration as maintenance therapy post-HSCT in IDH1- and IDH2-mutated AML, although larger prospective trials are required to confirm these results. A randomized phase II study of post-HSCT maintenance with ivosidenib vs. placebo in IDH1-mutant AML has been registered (NCT06707493) [48]. For non-transplant candidates, use of IDH inhibitors outside of clinical trials is not yet established. A phase 1 study of olutasidenib maintenance following HSCT is also currently recruiting (NCT06668584) [49].
Eprenetapopt, a first-in-class small-molecule p53 reactivator, has been tested in combination with azacitidine as maintenance therapy post-HSCT in patients with TP53-mutated AML or myelodysplastic syndrome (MDS) [50]. Phase II study (NCT03931291) [51] enrolling 55 patients, of whom 33 received maintenance treatment, administered eprenetapopt at 3.7 g once daily intravenously on days 1–4 combined with azacitidine 36 mg/m2 on days 1–5. The one-year RFS and OS probabilities were 60% and 79%, respectively, with median RFS and OS of 12.5 and 20.6 months [50]. The two parallel phase II trials (NCT03072043 and NCT03588078) [52] had also shown encouraging complete remission rates of 40–50% and molecular remission rates of 38% [53]. Treatment was well-tolerated with no increase in GVHD. These results were superior to previously published outcomes in TP53-mutated AML or MDS patients undergoing HSCT without subsequent maintenance, although the phase III trial (NCT03745716) [54] did not confirm efficacy.
Glasdegib, a Hedgehog pathway inhibitor, was used in a pilot study administering glasdegib for up to one year post-HSCT and demonstrated poor tolerability with frequent treatment interruptions and a relapse incidence of 55% at one year, leading investigators to conclude that it did not meaningfully reduce relapse risk [55]. Histone deacetylase inhibitors (HDACis) such as panobinostat have shown moderate antileukemic activity in advanced AML and MDS. In a phase I/II study of post-transplant panobinostat maintenance, 2-year OS and RFS were 81% and 75%, respectively, with toxicities largely reversible after drug interruption and no increased incidence of GVHD [56]. Vorinostat in combination with low-dose azacitidine is currently undergoing clinical evaluation (NCT03843528) [57].
Regarding maintenance failures, therapy with gemtuzumab ozogamicin (GO) was incorporated in the EORTC-GIMEMA AML 19 trial, in which low-dose GO was given monthly to elderly or unfit patients [58]. In this phase III trial, 237 patients received GO induction followed by maintenance GO if there was no progression of disease. Results improved median OS with GO compared to best supportive care, including transfusions and hydroxyurea [58]. Subsequent trials such as NOPHO AML 2004 [59] and HOVON 43 [60] did not show differences in DFS or OS, and GO is therefore not recommended for use as maintenance.
Tipifarnib was also explored as maintenance therapy based on the role of the RAS signaling pathway in myeloid malignancies. In a phase II maintenance trial, tipifarnib was given twice daily in patients with AML in CR1 and poor-risk cytogenetic or molecular features, showing a median DFS of 13.5 months [61]. The randomized phase III E2902 trial did not cross the pre-specified boundary to call the study positive, therefore failing to demonstrate improvement in DFS in the tipifarnib arm (8.9 vs. 5.3 months) [62], and it has not been FDA-approved [62].

6. Immunotherapies

In the setting of immunotherapy, multiple studies have explored prophylactic or pre-emptive strategies following IC or allo-HSCT. Although some of these studies may not be considered maintenance therapy in a strict sense, this approach is clinically important and warrants further investigation. Advances in MRD monitoring may further guide decision-making, potentially allowing these immunotherapeutic strategies to be tailored based on individual relapse risk. Recent studies investigating mechanisms of immune escape in AML after allo-HSCT have highlighted the distinctive immunologic microenvironment that develops post-transplant [63]. These findings suggest that future maintenance approaches in AML could harness immune system activity through monoclonal antibodies, bispecific antibodies, and other cellular therapies to suppress post-remission MRD [64].
Donor lymphocyte infusion (DLI) remains a well-established cellular immunotherapy used to elicit GVLE following allo-HSCT [65,66,67]. Prophylactic or preemptive DLI represents the most widely used immunotherapeutic strategy for relapse prevention after allo-HSCT [66,68]. Whether the benefit of DLI is greater with prophylactic compared with pre-emptive administration remains unclear. A recent comparative study demonstrated that prophylactic DLI administered early post-transplant (median 51 days) resulted in higher 2-year LFS (56.3% vs. 40.5%) and markedly reduced 2-year cumulative incidence of relapse (23.4% vs. 48.8%) compared to preemptive DLI triggered by MRD positivity [69]. These findings were corroborated by another multicenter study demonstrating higher 3-year PFS (63.4% vs. 53.0%) and significantly lower cumulative incidence of relapse (25.3% vs. 36.7%) with prophylactic versus preemptive DLI [70]. Nevertheless, both studies were limited by relatively small sample sizes and retrospective designs, and earlier matched-pair analyses suggested that the benefit of prophylactic DLI may be largely confined to patients with high-risk disease features. In this context, a registry-based matched-pair analysis from the European Society for Blood and Marrow Transplantation (EBMT) reported that while prophylactic DLI did not improve outcomes in the overall cohort, patients with high-risk AML experienced superior OS compared with matched controls (69.8% vs. 40.2%) [71]. Despite potential advantages, prophylactic DLI carries a significant risk of GVHD, particularly when given early [65]. EBMT registry study also reported cumulative incidences of grade 2–4 acute or cGVHD of 30.7% for prophylactic DLIs versus 11.9% for preemptive, with 6% of patients dying from DLI-induced GVHD [65]. Prophylactic DLI may be considered as early as day +90 to +100 post-transplant in patients without active GVHD or infection who have been off immunosuppression for at least one month; however, it does not reliably prevent early relapse and lacks a standardized dosing schedule [65].
Combining DLI with HMAs such as azacitidine has also shown promising results as a post-transplant maintenance or pre-emptive strategy, with acceptable tolerability and reductions in relapse rates in retrospective cohorts [72,73]. Current EBMT recommendations suggest considering prophylactic preemptive DLI for patients with high-risk biological features, refractory or advanced disease at transplant, or those receiving ex vivo T cell-depleted grafts, with the first one typically given after resolution of immunosuppression (>30 days), generally between 4 and 6 months post-allo-HSCT, and with dosing escalated every 4–6 weeks, guided by MRD, chimerism, and GVHD status [74].
Interferon alpha (IFNα) is a known antitumoral agent exerting both direct and indirect effects on leukemia cells. IFNα can reduce tumor cell proliferation by limiting the secretion of growth-promoting cytokines, increasing the immunogenicity of AML cells, modulating human leukocyte antigen (HLA) expression and activating cell-mediated cytotoxicity of T cells, NK cells, and dendritic cells towards tumor cells [75,76]. It has also been investigated in the post-allo-HSCT setting as a preemptive strategy rather than true maintenance. In a prospective pre-emptive-strategy study (NCT02027064) [77] of patients with t(8;21) AML and RUNX1/RUNX1T1 MRD positivity after allo-HSCT, treatment was associated with relatively low GVHD rates and an MRD clearance rate of 21.5% at more than 3 months from initiation [78]. In non-transplant AML, IFNα did not demonstrate a survival advantage when used as maintenance therapy. Two initial randomized clinical trials, one from Finland by Palva [79], and the other from the UK (MRC AML11 trial), failed to show a beneficial effect of IFNα maintenance on DFS or OS. However, a more recent Chinese retrospective study of 84 patients with favorable-risk AML found that IFNα maintenance (not MRD-driven) for 12–18 months led to improved 4-year RFS of 87% versus 56% and OS of 94% versus 76% compared to a historical control cohort [80]. A phase 3 clinical trial (NCT06802718) is indeed testing IFNα in adults with favorable-risk AML and positive MRD, reflecting renewed interest in this approach for selected patient populations [81]. While early maintenance studies of IFNα in unselected AML populations were largely negative, emerging data suggest the possible role of preemptive or targeted strategy in biologically defined, favorable-risk or MRD-positive patients, claiming for further evaluation. A phase I-/II-pegylated IFNα trial (NCT02328755) in 36 high-risk AML patients undergoing allo-HSCT administered every 2 weeks starting day −1 of transplant regardless of MRD status suggested potential reduction in early relapse [82]. The incidence of relapse was 39% at 6 months, which was sustained through 1-year post HSCT. The incidence of transplant-related mortality was 13% and severe grade III-IV GVHD occurred in 11%. No randomized trial of pegylated IFNα is currently registered.
Interleukin-2 (IL-2) was one of the earliest immunomodulatory agents evaluated as a maintenance therapy in AML. IL-2 regulates T cell differentiation and NK cell proliferation, activating antileukemic T and NK cells to reduce relapse risk. However, multiple early randomized clinical trials and subsequent systematic reviews and meta-analyses of IL-2 monotherapy after IC (no-transplant candidates) found no evidence of extended DFS or OS compared to control groups, indicating IL-2 monotherapy did not provide meaningful survival benefit [83]. When combined with HDC (high-dose cytarabine), a multicenter randomized phase III trial of 320 adult AML patients in first complete remission after induction and consolidation therapy, not proceeding to allo-HSCT, evaluated maintenance with HDC plus low-dose IL-2 versus observation. Patients received subcutaneous injections of HDC and IL-2 twice daily in alternating cycles over 18 months, typically 3 weeks of treatment followed by 3–6 weeks of rest. In this trial, 3-year LFS was significantly higher in the HDC/IL-2 arm compared with the control arm (40 vs. 26%; p = 0.01), although there was no statistically significant difference in OS [84]. These results led to EMA approval in 2008 of the combination for maintenance in adult AML patients in first CR [85]. An initial negative recommendation by the EMA’s committee early in 2008 was subsequently reversed upon re-examination, and a positive opinion and full marketing authorization were granted later in 2008. The regimen is thought to enhance the immune system’s ability to eliminate residual leukemic cells by protecting IL-2-activated lymphocytes from oxidative suppression. Despite approval, IL-2/HDC maintenance therapy is not widely used in routine practice, largely because overall clinical benefit—especially in OS—was modest relative to toxicity concerns and the logistical burden of prolonged subcutaneous therapy.
Lenalidomide has been explored in multiple contexts. A single-center phase I dose-escalation study evaluated lenalidomide maintenance after allo-HSCT in high-risk MDS and AML patients using a “3 + 3” design starting at 5 mg daily, increasing in 5 mg increments up to 15 mg [86]. Lenalidomide was given for 21 days of a 28-day cycle for six cycles. Most common dose-limiting toxicities were lymphopenia, diarrhea, nausea, and neutropenia. Two patients developed acute GVHD (aGVHD) and five developed cGVHD. The maximum tolerated dose was 10 mg, with dose-limiting toxicities observed at 15 mg. Limitations included initiation at ~6 months post-transplant, by which time many high-risk patients may relapse. Overall, lenalidomide was well-tolerated with minimal GVHD and low relapse rates [86]. When combined with azacitidine in a phase Ib study, lenalidomide demonstrated reasonable tolerability and some efficacy, with median RFS of approximately 11–12 months and median OS ranging from 20 months to not reached [87]. The HOVON-SAKK-132 trial was a phase 3 clinical trial that investigated the addition of lenalidomide given following induction and consolidation chemotherapy as well as during maintenance therapy [88]. The study did not find any OS or EFS benefit in patients receiving lenalidomide and there was no apparent benefit for maintenance either [88].
Nivolumab, a PD-1 immune checkpoint inhibitor, has also been investigated. Post-allo-HSCT low-dose nivolumab (1 mg/kg) was explored in a small cohort but the study was prematurely discontinued due to high GVHD rates and toxicity [89]. In the randomized phase II REMAIN trial (NCT02275533), 80 patients with AML in first CR were not candidates for allo-HSTC and were enrolled for observation or nivolumab (3 mg/kg IV every 2 weeks for 46 doses). The study did not demonstrate significant improvements PFS (13.2 months nivolumab vs. 10.9 months observation) or OS (53.9 months vs. 30.9 months, not statistically significant). There were substantially more adverse events on the nivolumab arm as follows: 27 patients (71%) had grade ≥ 3 AEs compared with five patients (12%) on observation (p < 0.001) [90]. Other immune checkpoint inhibitors have been explored in AML and post-transplant contexts. Ipilimumab induced responses in some post-transplant relapsed patients but was associated with severe immune-related adverse events, including fatal toxicity and significant GVHD, with similar increases in severe GVHD reported in lymphoid malignancies treated post-transplant. Sabatolimab, a TIM-3-targeting immunotherapy, has been evaluated post-HSCT in MRD-positive AML, with early data suggesting it is well-tolerated without inducing significant GVHD or immune toxicity. However, the STIMULUS-MDS1 trial did not meet its primary endpoints in higher-risk MDS. CR rates were similar between sabatolimab plus HMAs and placebo plus HMA (22% vs. 18%, p = 0.77), and there was no statistically significant improvement in PFS (11.1 vs. 8.5 months, HR 0.75, p = 0.10). The safety profile was manageable, with only one serious immune-mediated adverse event and one treatment-related death due to pneumonitis. Due to lack of efficacy demonstrated in clinical trials in AML and MDS, sabatolimab is no longer being developed in these indications [91].
WT1 (Wilms’ Tumor 1) is a highly attractive target for immunotherapy due to its strong expression in multiple malignancies, including AML. WT1 is expressed in 90–95% of AML blasts, in both peripheral blood and bone marrow, supporting the development of targeted therapies such as peptide vaccines [92,93]. In a phase II trial (NCT01266083) [94] of 22 patients in CR1 (median age 64), biweekly administration of a peptide vaccine—Galinpepimut-S (GPS), for six doses, with continuation to 12 doses in clinically stable patients—resulted in a 3-year OS of 47%, exceeding the prespecified endpoint of 34% and historical rates of 20–25% [95]. Median DFS was 16.9 months, and the vaccine was well-tolerated, with predominantly mild injection-site reactions. In a second trial (NCT00665002) [96] including 10 AML patients in second complete remission (CR2), GPS administration was associated with a median OS of 16.3 months versus 5.4 months in a historical cohort (p = 0.0175), along with a numerical improvement in median PFS (10.5 vs. 4.3 months). Durable responses were observed, with several patients remaining in remission throughout the treatment period. Overall, GPS was safe, immunogenic, and demonstrated encouraging survival outcomes, providing the rationale for further evaluation in phase III of REGAL trial (NCT04229979) [97].
Early-phase studies of engineered T-cell and NK-cell therapies for post-transplant relapse prevention in AML have demonstrated favorable safety and encouraging efficacy. Donor-derived TCR-engineered T cells targeting HA-1 (TSC-100) and HA-2 (TSC-101) were evaluated in phase 1 of ALLOHA trial (NCT05473910) [98], where 16 patients received one or two post-transplant infusions. No dose-limiting toxicities, cytokine release syndrome (CRS), ICANS, or TSC-related deaths were observed, and GVHD rates were comparable to controls [99]. At the July 2024 data cut, all TSC-treated patients remained MRD-negative and relapse-free, with complete donor chimerism, while 3 of 11 control patients relapsed. TSC therapy improved relapse-free probability at one year (p = 0.047) and EFS (HR 0.09, p = 0.025). Similarly, donor-derived or ex vivo-activated NK-cell therapies (e.g., KDS-1001; NCT05115630) were well-tolerated, supported engraftment, and showed low rates of aGVHD or infusion reactions. Overall, early results suggest these cellular immunotherapies may reduce relapse without increasing GVHD, but larger studies are needed to confirm long-term efficacy and optimal integration into post-transplant strategies.

7. Ongoing Clinical Trials

Several large, randomized phase III studies integrate targeted agents with intensive induction and consolidation, followed by maintenance, the studies are shown in Table 3. These include crenolanib versus midostaurin in newly diagnosed FLT3-mutated AML (NCT03258931) [100], with a sample size of 510 patients. This study aims to evaluate EFS over five years and allows transplantation when appropriate. The trial is active but no longer recruiting, and results are awaited given midostaurin’s role as the current standard of care. Similarly, gilteritinib versus midostaurin is being evaluated in the HOVON 156/AMLSG 28-18 trial (NCT04027309) [101], and ivosidenib and enasidenib versus placebo in IDH-mutated AML or MDS-EB2 is being studied in HOVON 150 (NCT03839771) [102]. Both trials have a primary endpoint of EFS and integrate intensive chemotherapy and transplant strategies, which may challenge midostaurin as the default partner to 7+3 depending on their outcomes. These three trials may also introduce a mutation-specific hierarchy within FLT3-mutated disease; however, maintenance decisions may still remain unclear, as no randomized trials specifically focused on maintenance strategies are currently registered.
Regarding the HOVON 150 trial, which enrolls nearly 1000 patients, results could establish targeted agent selection within intensive frontline therapy, not only in unfit or relapsed patients. The use of IDH inhibitors during frontline intensive chemotherapy would be a consideration if HOVON-150 demonstrates superior EFS for either ivosidenib or enasidenib. Because all three large induction trials allow allo-HSCT, their outcomes will inform whether certain targeted agents reduce relapse risk, potentially influencing which patients truly benefit from early allo-HSCT versus continued pharmacologic strategies.
In the post-allo HSCT transplant setting, targeted maintenance is being investigated in randomized and single-arm phase II trials using IDH inhibitors such as ivosidenib (NCT06707493) [48], enasidenib (NCT03728335; NCT04522895) [103,104], and olutasidenib (NCT06543381) [105], as well as the menin inhibitors revumenib (NCT06575296) [106] and ziftomenib (NCT06440135) [107]. The olutasidenib study aims to determine whether IDH1 inhibition post-transplant is feasible across AML, MDS, and chronic myelomonocytic leukemia (CMML). This is particularly relevant because IDH mutations are common, often persist at remission, and are biologically stable, making them attractive maintenance targets if long-term tolerability can be demonstrated.
All previously mentioned phase I/II post-HSCT trials may not immediately change clinical guidelines; however, they will add critical knowledge by defining whether targeted maintenance beyond FLT3 inhibition is tolerable and safe after allo-HSCT. These studies will help establish dosing windows, schedules, and toxicity profiles for menin inhibitors, IDH inhibitors, and antibody–drug conjugates during a vulnerable post-transplant period characterized by cytopenias, infections, GVHD, and drug–drug interactions. They may also help define optimal timing for initiation after HSCT—such as 30, 50, or 100 days post-transplant—by balancing immune reconstitution against relapse risk. Currently, timing decisions are largely based on expert opinion rather than prospective data, underscoring the need for evidence to standardize future protocols. Hopefully, consecutive phases of these trials would bring risk-adapted, mutation-directed maintenance strategies, transforming post-transplant care from passive surveillance into active, precision-based intervention.
There remains a substantial knowledge gap regarding the use of menin inhibitors in the post-allo-HSCT setting. A key unanswered question is whether these agents can suppress molecular relapse without impairing graft function. Serial MRD monitoring in small, genetically defined cohorts will be critical to determine whether post-HSCT targeted therapy can eradicate residual leukemic clones rather than merely delay overt relapse.
Several prospective studies investigating HMA-based maintenance strategies are also ongoing. The AMADEUS study (NCT04173533) [108] is a phase III placebo-controlled trial evaluating CC-486 maintenance for up to 12 months following allo-HSCT, with RFS as the primary endpoint. Enrollment was completed in April 2025, and results are pending. The VIALE-T study is a phase III open-label randomized controlled trial (NCT04161885) [109] comparing azacitidine plus venetoclax with best supportive care following transplant; enrollment was completed in September 2025, and results are anticipated.
Combination HMA-based strategies include venetoclax plus azacitidine in the VIALE-M trial (NCT04102020) [110]; oral decitabine/cedazuridine administered alone or in combination with venetoclax or targeted agents such as gilteritinib, enasidenib, or ivosidenib in mixed-intensity settings (NCT05010772) [111]; venetoclax plus cytarabine versus idarubicin (NCT04968015) [112]; and lenalidomide plus azacitidine in non-transplant candidates (NCT04490707) [113]. These trials aim to determine whether HMAs can function as long-term disease control strategies.
Mocravimod is an oral sphingosine-1-phosphate receptor modulator being investigated as post-transplant maintenance therapy to enhance GVLEs and reduce the risk of relapse following allo-HSCT. The phase III trial is evaluating its impact on RFS in patients with AML [114].
The ongoing REGAL trial compares GPS with investigator-selected best available therapy in patients with AML in second or later remission who are ineligible for allo-HSCT, with the aim of improving overall and relapse-free survival (NCT04229979) [97]. The study is overseen by an Independent Data Monitoring Committee; as of 26 December 2025, 72 events had been recorded, and final analysis will be performed after the 80th event. The results will provide further insight into the clinical activity of WT1-targeted vaccination strategies in AML.
In the post-transplant setting, immunomodulatory and adoptive cellular strategies are in early-phase development, including lenalidomide maintenance (NCT01254578) [115], ONC201 (NCT03932643) [116], γδ T-cell infusions (NCT05015426) [117], off-the-shelf natural killer cell products administered peri-HSCT (NCT05115630) [118], and T-cell receptor-engineered T-cell therapies delivered in the peri-transplant period (NCT05473910) [98]. Together, these studies will deepen understanding of immune surveillance and relapse biology in AML.
Table 3. Ongoing clinical trials, phase III.

8. Conclusions

Maintenance therapy in AML has evolved into an evidence-based treatment strategy that provides clinically meaningful benefit in selected patient populations. While reducing relapse risk without excessive toxicity remains the primary goal, optimal implementation continues to evolve.
From a practical standpoint, CC-486 should be considered standard of care in older patients with AML in CR1 who are not candidates for allo-HSCT, based on a demonstrated OS benefit in this setting. In FLT3-mutated AML, FLT3 inhibitors represent the most established maintenance approach, particularly in the post-transplant setting, where sorafenib and gilteritinib have shown clinically meaningful reductions in relapse risk, especially among MRD-positive patients.
In routine clinical practice, maintenance therapy is therefore best applied in a risk-adapted manner. Patients with high-risk disease features or persistent MRD positivity are the most likely to derive benefit and should be considered for maintenance strategies when supported by available evidence or clinical trial access. In contrast, MRD-negative patients without actionable mutations should generally be managed with observation, as there is currently insufficient evidence to support routine maintenance outside clinical trials.
The optimal duration and timing of therapy remain undefined. Post-transplant maintenance is commonly initiated between 30 and 100 days after allo-HSCT depending on immune reconstitution and relapse risk, while duration varies from fixed courses to continuation until progression or unacceptable toxicity. Importantly, interpretation of FLT3 inhibitor maintenance benefit is limited by trial designs in which targeted agents are introduced from induction onward, making it difficult to isolate the independent effect of the maintenance phase.
Emerging strategies, including IDH inhibitors, menin inhibitors, and immunotherapeutic approaches, are expanding the maintenance landscape but remain investigational. At present, these should be reserved for clinical trial settings. Integration of genomic profiling and serial MRD assessment will further refine patient selection and may allow treatment intensification or de-escalation based on individual relapse risk.
Overall, current evidence supports a precision-based, risk-adapted approach rather than uniform maintenance therapy. In practical terms, clinicians should prioritize:
(1)
CC-486 in eligible non-transplant patients in CR1;
(2)
FLT3 inhibitor maintenance post-transplant in FLT3-mutated disease, particularly if MRD-positive;
(3)
Clinical trial enrollment for all other maintenance strategies;
(4)
Observation for MRD-negative, lower-risk patients.
Ongoing phase III trials, including AMADEUS, VIALE-T, and multiple genetically targeted studies, will further define the role of maintenance therapy and may refine these recommendations. Cellular immunotherapies such as TCR-engineered T cells, NK cell products, and bispecific antibodies represent a promising future direction but remain experimental.
Finally, key unresolved questions include optimal treatment duration, timing relative to transplantation, sequencing with other targeted agents, and predictive biomarkers of both response and toxicity. Addressing these gaps will be essential to fully transition AML post-remission care toward a standardized precision-medicine framework.

Limitations

This review has several limitations. Evidence supporting maintenance therapy in AML remains heterogeneous, with many studies being single-center, retrospective, or limited by small sample sizes. In addition, differences in patient populations, MRD methodologies, and transplant practices complicate cross-trial comparisons. As a result, the optimal selection of patients for maintenance therapy remains an area of active investigation.

Author Contributions

Conceptualization, P.V., A.A. and D.S.; methodology, P.V., A.A. and D.S. (literature search and review of publications from the last 10 years on acute myeloid leukemia maintenance therapy); resources, P.V., A.A. and D.S. (literature and guideline sources including PubMed, ClinicalTrials.gov, EMA, FDA, Health Canada, NCCN, ELN, and EBMT guidelines); data curation, P.V., A.A. and D.S.; writing—original draft preparation, P.V., A.A. and D.S. (prepared using Microsoft Word); writing—review and editing, P.V., A.A. and D.S. (performed using Microsoft Word); visualization, P.V., A.A. and D.S. (tables designed using Microsoft PowerPoint and Microsoft Word); reference management, P.V. (using Zotero). All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created or analyzed in this study. Data supporting the findings of this study are derived from publicly available sources, including the published literature and clinical trial registries such as PubMed and ClinicalTrials.gov, as well as guidelines from regulatory and professional organizations.

Acknowledgments

The authors acknowledge the use of publicly available resources that supported the preparation of this manuscript, including ClinicalTrials.gov and OpenEvidence for identifying relevant clinical trials and the literature related to acute myeloid leukemia maintenance therapy. Reference organization and citation management were performed using Zotero. Figure was designed using Lucidchart (Lucid Software Inc., South Jordan, UT, USA; web-based diagramming software). During the preparation of this manuscript, the authors used ChatGPT (OpenAI, San Francisco, CA, USA; GPT-5.5) to assist with language editing and formatting. The authors reviewed and edited the output and take full responsibility for the content of this publication.

Conflicts of Interest

The authors declare the following conflicts of interest: David Sanford—Honoraria: Astellas Pharma, Abbvie Pharma, J&J Pharma, Servier Pharma.

Abbreviations

The following abbreviations are used in this manuscript:
ALWPAcute Leukemia Working Party
AMLAcute Myeloid Leukemia
allo-HSCTAllogeneic Hematopoietic Stem Cell Transplantation
CRComplete Remission
CRiComplete Remission with Incomplete Hematologic Recovery
DFSDisease-Free Survival
EBMTEuropean Society for Blood and Marrow Transplantation
EFSEvent-Free Survival
ELNEuropean LeukemiaNet
EMAsEuropean Medicines Agency
FDAU.S. Food and Drug Administration
FLT3FMS-like Tyrosine Kinase 3
FLT3-ITDFLT3 Internal Tandem Duplication
FLT3-TKDFLT3 Tyrosine Kinase Domain
GVHDGraft-versus-Host Disease
GVLEGraft-versus-Leukemia Effect
HMAHypomethylating Agent
ICIntensive Chemotherapy
IDHIsocitrate Dehydrogenase
MRDMeasurable Residual Disease
NCCNNational Comprehensive Cancer Network
NPM1Nucleophosmin 1
OSOverall Survival
RFSRelapse-Free Survival

References

  1. DiNardo, C.D.; Erba, H.P.; Freeman, S.D.; Wei, A.H. Acute Myeloid Leukaemia. Lancet Lond. Engl. 2023, 401, 2073–2086. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Bornhäuser, M.; Schliemann, C.; Schetelig, J.; Röllig, C.; Kramer, M.; Glass, B.; Platzbecker, U.; Burchert, A.; Hänel, M.; Müller, L.P.; et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2023, 9, 519–526. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Wei, A.H.; Döhner, H.; Pocock, C.; Montesinos, P.; Afanasyev, B.; Dombret, H.; Ravandi, F.; Sayar, H.; Jang, J.-H.; Porkka, K.; et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N. Engl. J. Med. 2020, 383, 2526–2537. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Sanz, J.; Bug, G.; Ciceri, F.; Craddock, C.; Dillon, R.; Esteve, J.; Porta, M.G.D.; Heuser, M.; de Leeuw, D.C.; Nagler, A.; et al. Measurable Residual Disease-Guided Interventions in Patients with Acute Myeloid Leukaemia Undergoing Allogeneic Haematopoietic Cell Transplantation: Best Practice Recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025, 26, e586–e596. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Bewersdorf, J.P.; Tallman, M.S.; Stahl, M. Maintenance Therapies in Acute Myeloid Leukemia: The Renaissance of an Old Therapeutic Concept. Curr. Opin. Oncol. 2021, 33, 658–669. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Kreidieh, F.; Abou Dalle, I.; Moukalled, N.; El-Cheikh, J.; Brissot, E.; Mohty, M.; Bazarbachi, A. Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: An Overview of Prevention and Treatment. Int. J. Hematol. 2022, 116, 330–340. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Xuan, L.; Liu, Q. Maintenance Therapy in Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. J. Hematol. Oncol. 2021, 14, 4. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Schuurhuis, G.J.; Heuser, M.; Freeman, S.; Béné, M.-C.; Buccisano, F.; Cloos, J.; Grimwade, D.; Haferlach, T.; Hills, R.K.; Hourigan, C.S.; et al. Minimal/Measurable Residual Disease in AML: A Consensus Document from the European LeukemiaNet MRD Working Party. Blood 2018, 131, 1275–1291. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Short, N.J.; Fu, C.; Berry, D.A.; Walter, R.B.; Freeman, S.D.; Hourigan, C.S.; Huang, X.; Gonzalez, G.N.; Hwang, H.; Qi, X.; et al. Association of Hematologic Response and Assay Sensitivity on the Prognostic Impact of Measurable Residual Disease in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Leukemia 2022, 36, 2817–2826. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Platzbecker, A.S.; Georgi, J.A.; Middeke, J.M.; Sockel, K.; Wehner, R.; Herbst, R.T.; Wolf, D.; Baldus, C.D.; Oelschlaegel, U.; Mütherig, A.; et al. Azacitidine to Treat Measurable Residual Disease in Patients with MDS/AML: Final Long-Term Results of the RELAZA2 Trial. Blood 2026, 147, 1098–1110. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Roboz, G.J.; Ravandi, F.; Wei, A.H.; Dombret, H.; Thol, F.; Voso, M.T.; Schuh, A.C.; Porkka, K.; La Torre, I.; Skikne, B.; et al. Oral Azacitidine Prolongs Survival of Patients with AML in Remission Independently of Measurable Residual Disease Status. Blood 2022, 139, 2145–2155. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Tiong, I.S.; Loo, S. Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. Int. J. Mol. Sci. 2023, 24, 4790. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Yanada, M.; Konuma, T.; Yamasaki, S.; Kondo, T.; Fukuda, T.; Shingai, N.; Sawa, M.; Ozawa, Y.; Tanaka, M.; Uchida, N.; et al. Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Clinical Features and Outcomes. Bone Marrow Transplant. 2021, 56, 1126–1133. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Döhner, H.; Wei, A.H.; Roboz, G.J.; Montesinos, P.; Thol, F.R.; Ravandi, F.; Dombret, H.; Porkka, K.; Sandhu, I.; Skikne, B.; et al. Prognostic Impact of NPM1 and FLT3 Mutations in Patients with AML in First Remission Treated with Oral Azacitidine. Blood 2022, 140, 1674–1685. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Huls, G.; Chitu, D.A.; Havelange, V.; Jongen-Lavrencic, M.; van de Loosdrecht, A.A.; Biemond, B.J.; Sinnige, H.; Hodossy, B.; Graux, C.; Kooy, R.v.M.; et al. Azacitidine Maintenance after Intensive Chemotherapy Improves DFS in Older AML Patients. Blood 2019, 133, 1457–1464. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Oran, B.; de Lima, M.; Garcia-Manero, G.; Thall, P.F.; Lin, R.; Popat, U.; Alousi, A.M.; Hosing, C.; Giralt, S.; Rondon, G.; et al. A Phase 3 Randomized Study of 5-Azacitidine Maintenance vs Observation after Transplant in High-Risk AML and MDS Patients. Blood Adv. 2020, 4, 5580–5588. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Gao, L.; Zhang, Y.; Wang, S.; Kong, P.; Su, Y.; Hu, J.; Jiang, M.; Bai, H.; Lang, T.; Wang, J.; et al. Effect of rhG-CSF Combined with Decitabine Prophylaxis on Relapse of Patients with High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J. Clin. Oncol. 2020, 38, 4249–4259. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Chua, C.C.; Hammond, D.; Kent, A.; Tiong, I.S.; Konopleva, M.Y.; Pollyea, D.A.; DiNardo, C.D.; Wei, A.H. Treatment-Free Remission after Ceasing Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Blood Adv. 2022, 6, 3879–3883. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Daver, N.; Schlenk, R.F.; Russell, N.H.; Levis, M.J. Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Leukemia 2019, 33, 299–312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Fedorov, K.; Maiti, A.; Konopleva, M. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. Cancers 2023, 15, 2312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Döhner, H.; Wei, A.H.; Appelbaum, F.R.; Craddock, C.; DiNardo, C.D.; Dombret, H.; Ebert, B.L.; Fenaux, P.; Godley, L.A.; Hasserjian, R.P.; et al. Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN. Blood 2022, 140, 1345–1377. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Antar, A.I.; Otrock, Z.K.; Jabbour, E.; Mohty, M.; Bazarbachi, A. FLT3 Inhibitors in Acute Myeloid Leukemia: Ten Frequently Asked Questions. Leukemia 2020, 34, 682–696. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Perl, A.E.; Martinelli, G.; Cortes, J.E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M.R.; Larson, R.A.; Ustun, C.; et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019, 381, 1728–1740. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Burchert, A.; Bug, G.; Fritz, L.V.; Finke, J.; Stelljes, M.; Röllig, C.; Wollmer, E.; Wäsch, R.; Bornhäuser, M.; Berg, T.; et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication Mutation (SORMAIN). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020, 38, 2993–3002. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Xuan, L.; Wang, Y.; Yang, K.; Shao, R.; Huang, F.; Fan, Z.; Chi, P.; Xu, Y.; Xu, N.; Deng, L.; et al. Sorafenib Maintenance after Allogeneic Haemopoietic Stem-Cell Transplantation in Patients with FLT3-ITD Acute Myeloid Leukaemia: Long-Term Follow-up of an Open-Label, Multicentre, Randomised, Phase 3 Trial. Lancet Haematol. 2023, 10, e600–e611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Diral, E.; Furnari, G.; Bruno, A.; Greco, R.; Clerici, D.; Marktel, S.; Farina, F.; Mastaglio, S.; Vago, L.; Piemontese, S.; et al. Sorafenib Maintenance in FLT3-ITD Mutated AML after Allogeneic HCT: A Real-World, Single-Center Experience. Front. Oncol. 2024, 14, 1391743. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Morin, S.; Giannotti, F.; Mamez, A.-C.; Pradier, A.; Masouridi-Levrat, S.; Simonetta, F.; Chalandon, Y. Real-World Experience of Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML Reveals High Rates of Toxicity-Related Treatment Interruption. Front. Oncol. 2023, 13, 1095870. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Fei, X.; Zhang, S.; Gu, J.; Wang, J. FLT3 Inhibitors as Maintenance Therapy Post Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations: A Meta-Analysis. Cancer Med. 2023, 12, 6877–6888. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Perl, A.E.; Larson, R.A.; Podoltsev, N.A.; Strickland, S.; Wang, E.S.; Atallah, E.; Schiller, G.J.; Martinelli, G.; Neubauer, A.; Sierra, J.; et al. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant. Cell. Ther. 2023, 29, 265.e1–265.e10. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Levis, M.J.; Hamadani, M.; Logan, B.R.; Jones, R.J.; Singh, A.K.; Litzow, M.R.; Wingard, J.R.; Papadopoulos, E.B.; Perl, A.E.; Soiffer, R.J.; et al. Measurable Residual Disease and Posttransplantation Gilteritinib Maintenance for Patients with FLT3-ITD-Mutated AML. Blood 2025, 145, 2138–2148. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Pollyea, D.A.; Altman, J.K.; Assi, R.; Bixby, D.; Fathi, A.T.; Foran, J.M.; Gojo, I.; Hall, A.C.; Jonas, B.A.; Kishtagari, A.; et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2023, 21, 503–513. [Google Scholar] [CrossRef] [Scilit]
  32. Cloos, J.; Valk, P.J.M.; Thiede, C.; Döhner, K.; Roboz, G.J.; Wood, B.L.; Walter, R.B.; Wang, S.A.; Wierzbowska, A.; Wei, A.H.; et al. 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood 2026, 147, 1147–1167. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Gyan, E.; Minden, M.D.; Kubo, K.; Rambaldi, A.; Juliusson, G.; Jädersten, M.; Kelly, R.J.; Szerafin, L.; He, W.; Gill, S.C.; et al. Maintenance Therapy with the FMS-like Tyrosine Kinase 3 Inhibitor Gilteritinib in Patients with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication Acute Myeloid Leukemia: A Phase 2 Study. Cancer 2025, 131, e35746. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Larson, R.A.; Mandrekar, S.J.; Huebner, L.J.; Sanford, B.L.; Laumann, K.; Geyer, S.; Bloomfield, C.D.; Thiede, C.; Prior, T.W.; Döhner, K.; et al. Midostaurin Reduces Relapse in FLT3-Mutant Acute Myeloid Leukemia: The Alliance CALGB 10603/RATIFY Trial. Leukemia 2021, 35, 2539–2551. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Maziarz, R.T.; Levis, M.; Patnaik, M.M.; Scott, B.L.; Mohan, S.R.; Deol, A.; Rowley, S.D.; Kim, D.D.H.; Hernandez, D.; Rajkhowa, T.; et al. Midostaurin after Allogeneic Stem Cell Transplant in Patients with FLT3-Internal Tandem Duplication-Positive Acute Myeloid Leukemia. Bone Marrow Transplant. 2021, 56, 1180–1189. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Erba, H.P.; Montesinos, P.; Kim, H.-J.; Patkowska, E.; Vrhovac, R.; Žák, P.; Wang, P.-N.; Mitov, T.; Hanyok, J.; Kamel, Y.M.; et al. Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Lond. Engl. 2023, 401, 1571–1583. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Cortes, J. Quizartinib: A Potent and Selective FLT3 Inhibitor for the Treatment of Patients with FLT3-ITD-Positive AML. J. Hematol. Oncol. 2024, 17, 111. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. U.S. Food and Drug Administration. FDA Approves Quizartinib for Newly Diagnosed Acute Myeloid Leukemia. 2024. Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia (accessed on 26 February 2026).
  39. Oran, B.; Marin, D.; Bashir, Q.; Ahmed, S.; Olson, A.L.; Popat, U.; Kebriaei, P.; Shpall, E.J.; Jain, V.; Champlin, R.E. Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML. Blood 2024, 144, 1497. [Google Scholar] [CrossRef] [Scilit]
  40. Center for Drug Evaluation and Research (CDER). FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia. U.S. Food and Drug Administration. 2024. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-new-drug-approval-idh1-positive-relapsed-or-refractory-acute-myeloid-leukemia (accessed on 13 June 2026).
  41. Center for Drug Evaluation and Research (CDER). FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation. U.S. Food and Drug Administration. 2025. Available online: https://pmc.ncbi.nlm.nih.gov/articles/PMC11703669/ (accessed on 13 June 2026).
  42. Center for Drug Evaluation and Research (CDER). FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. U.S. Food and Drug Administration, 2022. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-combination-azacitidine-newly-diagnosed (accessed on 13 June 2026).
  43. FDA Approves New Targeted Treatment for Relapsed or Refractory Acute Myeloid Leukemia|FDA. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia (accessed on 20 January 2026).
  44. de Botton, S.; Montesinos, P.; Schuh, A.C.; Papayannidis, C.; Vyas, P.; Wei, A.H.; Ommen, H.; Semochkin, S.; Kim, H.-J.; Larson, R.A.; et al. Enasidenib vs Conventional Care in Older Patients with Late-Stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial. Blood 2023, 141, 156–167. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Government of Canada. Health Professional Risk Communication. IDHIFA (Enasidenib Mesylate)—Market Withdrawal and Continued Access—Recalls, Advisories and Safety Alerts—Canada.Ca. Available online: https://recalls-rappels.canada.ca/en/alert-recall/idhifa-enasidenib-mesylate-market-withdrawal-and-continued-access (accessed on 20 January 2026).
  46. Fathi, A.T.; Kim, H.T.; Soiffer, R.J.; Levis, M.J.; Li, S.; Kim, A.S.; Mims, A.S.; DeFilipp, Z.; El-Jawahri, A.; McAfee, S.L.; et al. Enasidenib as Maintenance Following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies. Blood Adv. 2022, 6, 5857–5865. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Fathi, A.T.; Kim, H.T.; Soiffer, R.J.; Levis, M.J.; Li, S.; Kim, A.S.; DeFilipp, Z.; El-Jawahri, A.; McAfee, S.L.; Brunner, A.M.; et al. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2023, 29, 2034–2042. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Study Details|NCT06707493|Ivosidenib as Post-HSCT Maintenance for AML|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06707493 (accessed on 12 February 2026).
  49. Study Details|NCT06668584|A Phase II Open-Label Study of Olutasidenib Post-Transplant Maintenance Therapy for Patients with IDH1-Mutated Myeloid Malignancies|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06668584 (accessed on 12 February 2026).
  50. Mishra, A.; Tamari, R.; DeZern, A.E.; Byrne, M.T.; Gooptu, M.; Chen, Y.B.; Deeg, H.J.; Sallman, D.; Gallacher, P.; Wennborg, A.; et al. Eprenetapopt Plus Azacitidine after Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J. Clin. Oncol. 2022, 40, 3985–3993. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Study Details|NCT03931291|APR-246 in Combination with Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03931291 (accessed on 12 February 2026).
  52. Study Details|NCT03588078|Study of the Safety and Efficacy of APR-246 in Combination with Azacitidine|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03588078 (accessed on 12 February 2026).
  53. Cluzeau, T.; Sebert, M.; Rahmé, R.; Cuzzubbo, S.; Lehmann-Che, J.; Madelaine, I.; Peterlin, P.; Bève, B.; Attalah, H.; Chermat, F.; et al. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone Des Myélodysplasies (GFM). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 1575–1583. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Study Details|NCT03745716|APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03745716 (accessed on 12 February 2026).
  55. Kent, A.; Vasu, S.; Schatz, D.; Monson, N.; Devine, S.; Smith, C.; Gutman, J.A.; Pollyea, D.A. Glasdegib as Maintenance Therapy for Patients with AML and MDS Patients at High Risk for Postallogeneic Stem Cell Transplant Relapse. Blood Adv. 2020, 4, 3102–3108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Bug, G.; Burchert, A.; Wagner, E.-M.; Kröger, N.; Berg, T.; Güller, S.; Metzelder, S.K.; Wolf, A.; Hünecke, S.; Bader, P.; et al. Phase I/II Study of the Deacetylase Inhibitor Panobinostat after Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML (PANOBEST Trial). Leukemia 2017, 31, 2523–2525. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Study Details|NCT03843528|Epigenetic Modification for Relapse Prevention: A Dose-Finding Study of Vorinostat Used in Combination with Low-Dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03843528 (accessed on 13 June 2026).
  58. Amadori, S.; Suciu, S.; Selleslag, D.; Aversa, F.; Gaidano, G.; Musso, M.; Annino, L.; Venditti, A.; Voso, M.T.; Mazzone, C.; et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016, 34, 972–979. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Hasle, H.; Abrahamsson, J.; Forestier, E.; Ha, S.-Y.; Heldrup, J.; Jahnukainen, K.; Jónsson, Ó.G.; Lausen, B.; Palle, J.; Zeller, B.; et al. Gemtuzumab Ozogamicin as Postconsolidation Therapy Does Not Prevent Relapse in Children with AML: Results from NOPHO-AML 2004. Blood 2012, 120, 978–984. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  60. Löwenberg, B.; Beck, J.; Graux, C.; van Putten, W.; Schouten, H.C.; Verdonck, L.F.; Ferrant, A.; Sonneveld, P.; Jongen-Lavrencic, M.; von Lilienfeld-Toal, M.; et al. Gemtuzumab Ozogamicin as Postremission Treatment in AML at 60 Years of Age or More: Results of a Multicenter Phase 3 Study. Blood 2010, 115, 2586–2591. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  61. Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; et al. Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 3077–3082. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  62. Luger, S.M.; Wang, V.X.; Rowe, J.M.; Litzow, M.R.; Paietta, E.; Ketterling, R.P.; Lazarus, H.; Rybka, W.B.; Craig, M.D.; Karp, J.; et al. Tipifarnib as Maintenance Therapy Did Not Improve Disease-Free Survival in Patients with Acute Myelogenous Leukemia at High Risk of Relapse: Results of the Phase III Randomized E2902 Trial. Leuk. Res. 2021, 111, 106736. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Toffalori, C.; Zito, L.; Gambacorta, V.; Riba, M.; Oliveira, G.; Bucci, G.; Barcella, M.; Spinelli, O.; Greco, R.; Crucitti, L.; et al. Immune Signature Drives Leukemia Escape and Relapse after Hematopoietic Cell Transplantation. Nat. Med. 2019, 25, 603–611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Sterling, C.; Webster, J. Harnessing the Immune System after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia. Am. J. Hematol. 2020, 95, 529–547. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Pagliuca, S.; Schmid, C.; Santoro, N.; Simonetta, F.; Battipaglia, G.; Guillaume, T.; Greco, R.; Onida, F.; Sánchez-Ortega, I.; Yakoub-Agha, I.; et al. Donor Lymphocyte Infusion after Allogeneic Haematopoietic Cell Transplantation for Haematological Malignancies: Basic Considerations and Best Practice Recommendations from the EBMT. Lancet Haematol. 2024, 11, e448–e458. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Schonewille, P.; van Rhenen, A.; Ham, R.M.T.; de Witte, M.; Kuball, J. Posttransplant Cells for the Win? DLI and Adoptive Cell Therapy to Eradicate MRD. Hematol. Am. Soc. Hematol. Educ. Program 2025, 2025, 537–546. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Maurer, K.; Antin, J.H. The Graft versus Leukemia Effect: Donor Lymphocyte Infusions and Cellular Therapy. Front. Immunol. 2024, 15, 1328858. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  68. Harada, K. Pre-Emptive and Prophylactic Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation. Int. J. Hematol. 2023, 118, 158–168. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Wu, N.; Yan, C.-H.; Kong, J.; Lv, M.; Mo, X.-D.; Sun, Y.-Q.; Cheng, Y.-F.; Xu, L.-P.; Zhang, X.-H.; Huang, X.-J.; et al. Prophylactic Versus Preemptive Donor Lymphocyte Infusion in Refractory/Relapsed AML Post-Allogeneic Transplant: A Retrospective Comparative Study. Transplant. Cell. Ther. 2026, 32, 302.e1–302.e10. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Yang, L.; Lai, X.; Yang, T.; Lu, Y.; Liu, L.; Shi, J.; Zhao, Y.; Wu, Y.; Chen, Y.; Yu, J.; et al. Prophylactic versus Preemptive Modified Donor Lymphocyte Infusion for High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study. Bone Marrow Transplant. 2024, 59, 85–92. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Schmid, C.; Labopin, M.; Schaap, N.; Veelken, H.; Schleuning, M.; Stadler, M.; Finke, J.; Hurst, E.; Baron, F.; Ringden, O.; et al. Prophylactic Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation in Acute Leukaemia—A Matched Pair Analysis by the Acute Leukaemia Working Party of EBMT. Br. J. Haematol. 2019, 184, 782–787. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  72. Liberatore, C.; Stanghellini, M.T.L.; Lorentino, F.; Vago, L.; Carrabba, M.G.; Greco, R.; Marktel, S.; Assanelli, A.; Farina, F.; Corti, C.; et al. Azacitidine and Donor Lymphocytes Infusions in Acute Myeloid Leukemia and Myelodysplastic Syndrome Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Donors. Ther. Adv. Hematol. 2022, 13, 20406207221090882. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Guillaume, T.; Thépot, S.; Peterlin, P.; Ceballos, P.; Bourgeois, A.L.; Garnier, A.; Orvain, C.; Giltat, A.; François, S.; Bris, Y.L.; et al. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse Following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplant. Cell. Ther. 2021, 27, 839.e1–839.e6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Prophylactic and Pre-Emptive Donor Lymphocyte Infusion in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: Validation of Current Recommendations and Proposal of a Modified Outcome Assessment. Haematologica 2025, 110, 2293–2304. [CrossRef] [Scilit] [PubMed]
  75. Healy, F.M.; Dahal, L.N.; Jones, J.R.E.; Floisand, Y.; Woolley, J.F. Recent Progress in Interferon Therapy for Myeloid Malignancies. Front. Oncol. 2021, 11, 769628. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Anguille, S.; Lion, E.; Willemen, Y.; Van Tendeloo, V.F.I.; Berneman, Z.N.; Smits, E.L.J.M. Interferon-α in Acute Myeloid Leukemia: An Old Drug Revisited. Leukemia 2011, 25, 739–748. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  77. Study Details|NCT02027064|Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT02027064 (accessed on 12 February 2026).
  78. Mo, X.-D.; Wang, Y.; Zhang, X.-H.; Xu, L.-P.; Yan, C.-H.; Chen, H.; Chen, Y.-H.; Qin, Y.-Z.; Liu, K.-Y.; Huang, X.-J. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist 2018, 23, 1349–1357. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Palva, I.P.; Almqvist, A.; Elonen, E.; Hänninen, A.; Jouppila, J.; Järventie, G.; Koivunen, E.; Kätkä, K.; Lahtinen, R.; Oivanen, T. Value of Maintenance Therapy with Chemotherapy or Interferon during Remission of Acute Myeloid Leukaemia. Eur. J. Haematol. 1991, 47, 229–233. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  80. Jiang, H.; Liu, X.-H.; Kong, J.; Wang, J.; Jia, J.-S.; Lu, S.-Y.; Gong, L.-Z.; Zhao, X.-S.; Jiang, Q.; Chang, Y.-J.; et al. Interferon-α as Maintenance Therapy Can Significantly Reduce Relapse in Patients with Favorable-Risk Acute Myeloid Leukemia. Leuk. Lymphoma 2021, 62, 2949–2956. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  81. Study Details|NCT06802718|Interferon-Alpha As Maintenance Therapy for Favorable-Risk Acute Myeloid Leukemia|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06802718 (accessed on 12 February 2026).
  82. Study Details|NCT02328755|Peginterferon Alfa-2a to Enhance Anti-Leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT02328755 (accessed on 12 February 2026).
  83. Mao, C.; Fu, X.-H.; Yuan, J.-Q.; Yang, Z.-Y.; Huang, Y.-F.; Ye, Q.-L.; Wu, X.-Y.; Hu, X.-F.; Zhai, Z.-M.; Tang, J.-L. Interleukin-2 as Maintenance Therapy for Children and Adults with Acute Myeloid Leukaemia in First Complete Remission. Cochrane Database Syst. Rev. 2015, 2015, CD010248. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Brune, M.; Castaigne, S.; Catalano, J.; Gehlsen, K.; Ho, A.D.; Hofmann, W.-K.; Hogge, D.E.; Nilsson, B.; Or, R.; Romero, A.I.; et al. Improved Leukemia-Free Survival after Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myeloid Leukemia: Results of a Randomized Phase 3 Trial. Blood 2006, 108, 88–96. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Ceplene|European Medicines Agency (EMA). Available online: https://www.ema.europa.eu/en/documents/overview/ceplene-epar-medicine-overview_en.pdf (accessed on 22 January 2026).
  86. Pham, B.; Hoeg, R.; Krishnan, R.; Richman, C.; Tuscano, J.; Abedi, M. Safety and Tolerability of Lenalidomide Maintenance in Post-Transplant Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Bone Marrow Transplant. 2021, 56, 2975–2980. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Feng, Y.; Chen, T.; Zhang, Y.; Yao, H.; Wang, P.; Wang, L.; Cassady, K.; Zou, Z.; Liu, Y.; Zhao, L.; et al. Azacitidine and Lenalidomide Combination: A Novel Relapse Prophylaxis Regimen after Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia. Front. Immunol. 2023, 14, 1182251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Löwenberg, B.; Pabst, T.; Maertens, J.; Gradowska, P.; Biemond, B.J.; Spertini, O.; Vellenga, E.; Griskevicius, L.; Tick, L.W.; Jongen-Lavrencic, M.; et al. Addition of Lenalidomide to Intensive Treatment in Younger and Middle-Aged Adults with Newly Diagnosed AML: The HOVON-SAKK-132 Trial. Blood Adv. 2021, 5, 1110–1121. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Hu, Y.; Wang, Y.; Min, K.; Zhou, H.; Gao, X. The Influence of Immune Checkpoint Blockade on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. Front. Immunol. 2024, 15, 1491330. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Pyzer, A.R.; Dillon, L.W.; Sharon, E.; Karrison, T.G.; Zha, Y.; Fulton, N.; Gui, G.; Andrew, G.; Streicher, H.; Sweet, K.; et al. Randomized Phase 2 Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Adv. 2025, 9, 2144–2152. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Zeidan, A.M.; Giagounidis, A.; Sekeres, M.A.; Xiao, Z.; Sanz, G.F.; Hoef, M.V.; Ma, F.; Hertle, S.; Santini, V. STIMULUS-MDS2 Design and Rationale: A Phase III Trial with the Anti-TIM-3 Sabatolimab (MBG453) + Azacitidine in Higher Risk MDS and CMML-2. Future Oncol. 2023, 19, 631–642. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Ogasawara, M. Wilms’ Tumor 1 -Targeting Cancer Vaccine: Recent Advancements and Future Perspectives. Hum. Vaccines Immunother. 2024, 20, 2296735. [Google Scholar] [CrossRef] [Scilit]
  93. Barbullushi, K.; Rampi, N.; Serpenti, F.; Sciumè, M.; Fabris, S.; De Roberto, P.; Fracchiolla, N.S. Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand? Cancers 2022, 14, 2994. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Study Details|NCT01266083|WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT01266083 (accessed on 12 February 2026).
  95. Maslak, P.G.; Dao, T.; Bernal, Y.; Chanel, S.M.; Zhang, R.; Frattini, M.; Rosenblat, T.; Jurcic, J.G.; Brentjens, R.J.; Arcila, M.E.; et al. Phase 2 Trial of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Acute Myeloid Leukemia. Blood Adv. 2018, 2, 224–234. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Study Details|NCT00665002|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients with Myeloid Neoplasms|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT00665002 (accessed on 12 February 2026).
  97. Jamy, O.; Cicic, D. REGAL: Galinpepimut-S vs. Best Available Therapy as Maintenance Therapy for Acute Myeloid Leukemia in Second Remission. Future Oncol. 2025, 21, 73–81. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Study Details|NCT05473910|A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT05473910 (accessed on 12 February 2026).
  99. Krakow, E.F.; Brault, M.; Summers, C.; Cunningham, T.M.; Biernacki, M.A.; Black, R.G.; Woodward, K.B.; Vartanian, N.; Kanaan, S.B.; Yeh, A.C.; et al. HA-1-Targeted T-Cell Receptor T-Cell Therapy for Recurrent Leukemia after Hematopoietic Stem Cell Transplantation. Blood 2024, 144, 1069–1082. [Google Scholar] [CrossRef] [Scilit]
  100. Study Details|NCT03258931|Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03258931 (accessed on 28 January 2026).
  101. Study Details|NCT04027309|A Study of Gilteritinib Versus Midostaurin in Combination with Induction and Consolidation Therapy Followed by One-Year Maintenance in Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes with Excess Blasts-2 with FLT3 Mutations Eligible for Intensive Chemotherapy|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04027309 (accessed on 28 January 2026).
  102. Study Details|NCT03839771|A Study of Ivosidenib or Enasidenib in Combination with Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, with an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03839771 (accessed on 28 January 2026).
  103. Study Details|NCT03728335|Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients with IDH2 Mutation|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03728335 (accessed on 28 January 2026).
  104. Study Details|NCT04522895|IDH2-Post-Allo-Trial for Patients with IDH2-Mut Myeloid Neoplasms After Allo-SCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04522895 (accessed on 28 January 2026).
  105. Study Details|NCT06543381|Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06543381 (accessed on 28 January 2026).
  106. Study Details|NCT06575296|Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06575296 (accessed on 28 January 2026).
  107. Study Details|NCT06440135|Ziftomenib Maintenance Post Allo-HCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT06440135 (accessed on 28 January 2026).
  108. Study Details|NCT04173533|Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04173533 (accessed on 28 January 2026).
  109. Study Details|NCT04161885|A Study Evaluating Safety and Efficacy of Venetoclax in Combination with Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants with Acute Myeloid Leukemia (AML)|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04161885 (accessed on 28 January 2026).
  110. Study Details|NCT04102020|A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04102020 (accessed on 28 January 2026).
  111. Study Details|NCT05010772|Decitabine Alone or in Combination with Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT05010772 (accessed on 28 January 2026).
  112. Study Details|NCT04968015|Venetoclax + Cytarabine Versus Idarubicin + Cytarabine: Efficacity Assessment as Post-Remission Therapy to Elderly Patients with Acute Myeloid Leukemia in First Remission|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04968015 (accessed on 28 January 2026).
  113. Study Details|NCT04490707|Study of Azacytidine Combined with Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT04490707 (accessed on 28 January 2026).
  114. Study Details|NCT05429632|Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT05429632 (accessed on 14 February 2026).
  115. Study Details|NCT01254578|Lenalidomide After Donor Bone Marrow Transplant in Treating Patients with High-Risk Hematologic Cancers|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT01254578 (accessed on 28 January 2026).
  116. Study Details|NCT03932643|ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT03932643 (accessed on 28 January 2026).
  117. Study Details|NCT05015426|Gamma Delta T-Cell Infusion for AML at High Risk of Relapse After Allo HCT|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT05015426 (accessed on 28 January 2026).
  118. Study Details|NCT05115630|Off-the-Shelf NK Cells + SCT for Myeloid Malignancies|ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/study/NCT05115630 (accessed on 28 January 2026).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.